Form D · Pharmaceuticals

TELYRX HOLDINGS INC.

Toronto, A6 · CIK 0002113853

Offering snapshot reported Apr 20, 2026 · SEC filing

Reported sold
$12.6M
Offering amount: $12.6M
Investors reported
51
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 31, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 20, 2026Initial$12,623,935No comparison51SEC filing

Offering details

Securities
Equity, Security to be acquired, Other
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-581154
Amount of offering represents the value of the shares exchanged for Issuer's equities. No cash consideration was paid.
Common shares exchanged for subscription receipts without further consideration.

Source: Form D, filed Apr 20, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kenneth Bernard Director
Andrew Brandt Director
John Eric Cascio Executive
John Eustice Executive
Robert Sean Foley Director
Adam Gardner Executive
Michael Handler Director
Rafael Jose Executive
Ransom Langford Director
Peter Lloyd Executive
Vanessa Slowey Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
333 Bay Street, Suite 2400
Toronto, A6, M5H 2T6
Phone: 800-878-1660